• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Evaluating fluticasone furoate plus vilanterol for the treatment of chronic obstructive pulmonary disease (COPD)
【24h】

Evaluating fluticasone furoate plus vilanterol for the treatment of chronic obstructive pulmonary disease (COPD)

机译：评估氟替辛呋喃酸盐加质甾醇治疗慢性阻塞性肺病（COPD）

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Inhaled corticosteroid/long-acting beta-2 agonists (ICS/LABA) combination inhalers have been a lifeline for a generation of chronic obstructive pulmonary disease (COPD) and asthma patients. Fluticasone furoate and Vilanterol (FF/VI) as a once-daily ICS/LABA combination have an extensive clinical trial and real-world data to support its use in COPD patients. Areas covered: The authors provide pharmacological profiles of fluticasone furoate, vilanterol and the FF/VI fixed dose combination. Salient clinical trials evaluating efficacy and safety of the FF/VI combination, and studies demonstrating the impact on COPD exacerbation risk and mortality are also discussed. Expert opinion: ICS/LABA combinations provide bronchodilation and decrease the frequency of COPD exacerbations. Individualizing treatment of each COPD patient based on unique phenotypes will maximize chances of therapeutic responsiveness. Asthma-COPD overlap (ACO), patients with sputum and/or blood eosinophilia, patients with a brisk bronchodilator response, and patients with frequent exacerbations are more likely to show a therapeutic response to ICS than populations who have none of these features. FF/VI will likely remain a popular ICS/LBA combination to treat COPD, as a once-daily inhaled therapy delivered via the Ellipta device popular with COPD patients, with extensive clinical trial and real-world data to support its use.
机译：简介：吸入皮质类固醇/长效β-2激动剂（ICS / Laba）组合吸入器是一代慢性阻塞性肺病（COPD）和哮喘患者的生命线。氟替塞呋喃（FF / VI）作为曾经每日IC / Laba组合具有广泛的临床试验和现实世界数据，以支持其在COPD患者中的使用。所涵盖的区域：作者提供氟替卡松呋塞，类维罗醇和FF / VI定期剂量组合的药理谱。还讨论了评估FF / VI组合的疗效和安全性的突出临床试验以及表现出对COPD加剧风险和死亡率影响的研究。专家意见：IC / Laba组合提供支气管扩张并降低COPD恶化的频率。基于独特表型的每个COPD患者的个性化治疗将最大限度地提高治疗响应性的机会。哮喘 - COPD重叠（ACO），痰和/或血嗜酸性粒细胞患者，患有患有轻快的支气管扩张剂反应的患者，以及频繁恶化的患者更有可能显示对IC的治疗反应，而不是那些没有这些特征的人群。 FF / VI可能仍然是一个受欢迎的IC / LBA组合来治疗COPD，作为通过埃拉米特设备流行的曾经的每日吸入治疗，具有广泛的临床试验和现实世界，以支持其使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号